Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, ProKidney Corp (NASDAQ: PROK) closed at $2.81 up 4.07% from its previous closing price of $2.7. In other words, the price has increased by $4.07 from its previous closing price. On the day, 1.91 million shares were traded. PROK stock price reached its highest trading level at $2.87 during the session, while it also had its lowest trading level at $2.6305.
Ratios:
For a deeper understanding of ProKidney Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.48 and its Current Ratio is at 11.48.
On September 10, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $6.Guggenheim initiated its Buy rating on September 10, 2024, with a $6 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 08 ’25 when Weber Darin J. sold 103,480 shares for $3.02 per share. The transaction valued at 312,510 led to the insider holds 0 shares of the business.
DARIN J WEBER bought 103,480 shares of PROK for $62,761 on Jul 08 ’25. On Apr 22 ’25, another insider, Control Empresarial de Capital, who serves as the Add’l Rep. Persons-see Ex.99-1 of the company, bought 387,393 shares for $0.71 each. As a result, the insider paid 276,366 and bolstered with 73,842,723 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 829699904 and an Enterprise Value of 1430974848. For the stock, the TTM Price-to-Sale (P/S) ratio is 1560.25. Its current Enterprise Value per Revenue stands at 2715.322 whereas that against EBITDA is -8.408.
Stock Price History:
The Beta on a monthly basis for PROK is 1.82, which has changed by 0.35000002 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $7.13, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is 1.12%, while the 200-Day Moving Average is calculated to be 55.49%.
Shares Statistics:
For the past three months, PROK has traded an average of 2.12M shares per day and 1550090 over the past ten days. A total of 133.42M shares are outstanding, with a floating share count of 97.78M. Insiders hold about 27.57% of the company’s shares, while institutions hold 30.14% stake in the company. Shares short for PROK as of 1760486400 were 10736252 with a Short Ratio of 5.06, compared to 1757894400 on 10116244. Therefore, it implies a Short% of Shares Outstanding of 10736252 and a Short% of Float of 11.03.
Earnings Estimates
. The current assessment of ProKidney Corp (PROK) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.09 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.44 and -$0.63 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.54, with 5.0 analysts recommending between -$0.38 and -$0.75.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of -$32.5k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is -$230k.
